NCT05319405已完成不适用
A Pilot Investigation of the Effectiveness of the Sana Device in Management of PTSD: A Blinded Randomized Controlled Trial
Sana Health2 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2023年4月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 46
- 试验地点
- 2
- 主要终点
- To examine the difference between Sana plus Treatment as Usual (Sana+TAU) and Treatment as Usual (TAU) on changes in PTSD symptoms as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) after 28 days.
研究概览
简要总结
The purpose of this study is to assess the effectiveness of the Sana Device when added to Treatment as Usual in participants with a diagnosis of post-traumatic stress disorder (PTSD)
详细描述
This is a study designed to assess the effectiveness of the Sana Device when added to Treatment as Usual in participants with a diagnosis of post-traumatic stress disorder (PTSD) on severity of symptoms as measured by CAPS-5. We will use a 2-arm repeated measures randomized controlled design in which participants will be randomly assigned to either Sana plus Treatment as Usual (Sana+TAU) or Treatment as Usual (TAU).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Having served, or are currently serving, in the US military with a VA CPRS record.
- •Willing to and capable of providing written electronic informed consent prior to the conduct of any study-related procedures.
- •Adults, of any sex or gender, 18 to 65 years of age.
- •Diagnosis of PTSD as determined by a Clinician Administered PTSD Scale for DSM-5 (CAPS-5) clinical interview or CAPS-5 severity ≥
- •Must be in good physical health based on self-report.
- •Any psychotropic drug therapy regimen must be stable (unchanging) for at least 4 weeks prior to enrollment and remain steady throughout the study.
- •Willing and able to comply with the study requirements, complete study assessments, and participate at scheduled times for the duration of the study.
- •Able to understand, speak, and read English sufficient for the completion of study assessments.
- •Provision of appropriate storage and charging for study equipment in a generally safe and dry condition.
排除标准
- •Pregnant, intending to become pregnant, or lactating females as self-reported.
- •History or presence of photo-sensitive epilepsy or other photo-sensitive conditions as self-reported.
- •History or presence of condition(s) that may affect balance, such as seizure disorders or vertigo as self-reported.
- •History or presence of severe and continuous tinnitus, at investigator discretion
- •Surgery or trauma requiring rehabilitation within the last 12 weeks as self-reported. Presence of cancer pain, acute pain following injury or other severe pain that would be anticipated to change during the course of the study, at discretion of the investigator.
- •Vision impairments that affect perception of light, color, or brightness in one or both eyes, and differences in visual perception between eyes, per patient self-report.
- •Deafness in one or both ears, perceived differences in hearing between ears, per patient self-report.
- •Current ear or eye infection, untreated allergies, or acute illness that may affect eyes or hearing (e.g., due to congestion), per patient self-report.
- •Presence of inflammation or broken skin around the eyes in the area of the mask, per patient self-report.
- •Presence of narcolepsy or untreated sleep apnea, per patient self-report. Note: presence of sleep apnea is permitted, so long as patients feel comfortable to use both apnea mask and Sana device in conjunction.
- •Participation in any other clinical study in which medication(s) are being delivered or have used an investigational drug or device within the last 30 days.
- •Any pending legal action that could prohibit participation or compliance in the study, per patient self-report.
- •Recent history of or current evidence of suicidal intent or active suicidal behavior based on patient self-report at investigator discretion.
- •Significant medical conditions or other circumstances which, in the opinion of the investigator, would preclude compliance with the protocol, adequate cooperation in the study or obtaining informed consent, or may prevent the patient from safely participating in study.
- •Employment by the investigator or the study site, with direct involvement in the proposed study or other studies under the direction of the investigator or study site, or a family member of an employee or of the investigator.
- •Use of drugs that can produce hallucinogenic effects (i.e., Ketamine or psilocybin mushrooms) within the past 4 weeks.
结局指标
主要结局
To examine the difference between Sana plus Treatment as Usual (Sana+TAU) and Treatment as Usual (TAU) on changes in PTSD symptoms as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) after 28 days.
时间窗: Baseline and Day 28
A 30-item structured interview that can be used to diagnosis and assess PTSD symptoms and severity.
次要结局
- To examine the difference between Sana+TAU and TAU on changes in PTSD symptoms as measured by the PTSD Checklist - 20-item scale for DSM-5 (PCL-5) after 28 days.(Baseline, Days 14 and 28)
- To examine the difference between Sana+TAU and TAU on anxiety symptoms as measured by the Generalized Anxiety Disorder 7-item scale (GAD-7) after 28 days.(Baseline, Days 14 and 28)
- To examine the difference between Sana+TAU and TAU on depression symptoms as measured by the Patient Health Questionnaire 9 (PHQ-9) after 28 days.(Baseline, Days 14 and 28)
- To examine the difference between Sana+TAU compared to TAU on perceived change in quality of life over TAU as measured by the Patient Global Impression of Change scale (PGIC) after 28 days.(Baseline, Days 14 and 28)
研究者
研究点 (2)
Loading locations...
相似试验
终止
不适用
Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 DiabetesType 2 DiabetesNCT02130401Scion NeuroStim6
尚未招募
2 期
A Study to find the Effectiveness of Siddha treatment for Vathakarsanam (Diabetic Peripheral Neuropathy)CTRI/2024/06/069492I
已完成
不适用
Tolerance and Efficacy of a Predigested, High Protein, High Omega 3 Fat Enteral Feeding Formula Versus a Standard Formula In Multiple Intensive Care Unit SettingsCritical IllnessEnteral FeedingNCT01448135Columbia University50
已完成
不适用
A Pilot Study to Examine the Impact of a Therapy Dog Intervention on Loneliness and Related Health Outcomes in Vulnerable PopulationsLonelinessQuality of LifeDepressionAnxietyNCT05089201Virginia Commonwealth University72
已完成
不适用
The impact of therapeutic Human Immunodeficiency Virus (HIV) vaccination followed by antiretroviral therapy in patients with prolonged viral suppressioHuman Immunodeficiency Virus (HIV)Infections and InfestationsHuman immunodeficiency virus (HIV)ISRCTN87061665Ottawa Hospital Research Institute (Canada)60